Medical device firm AngioDynamics has started the enrollment of patients in its Registry of AngioVac Procedures In Detail (RAPID) Database at University of California-Los Angeles (UCLA) Health in Los Angeles.
The RAPID Database has been designed to assess the patterns of use, as well as safety and effectiveness data of the AngioVac system in the en bloc removal of fresh, soft thrombi or emboli.
UCLA Cardiology-Interventional Radiology Innovation director and national principal investigator Dr John Moriarty said: "So far, we have centers in 31 states that want to take part in the Registry.
"Our goal is to include as many potential collaborators as possible, and start gathering much needed data regarding procedural and patient outcomes."
According to the firm, RAPID’s primary objective is to capture high quality patient safety and effectiveness data on use of the AngioVac system for various anatomic locations.
This objective will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for all patients who have the AngioVac catheter deployed into their venous system.
The secondary objectives of RAPID are studying, assessing and benchmarking clinical practice patterns and these will be achieved through the capture of selected process data for patients included in the registry.
Data from the study will also be used to develop and refine standards of care for use of AngioVac and to facilitate the design of randomized clinical trials.